drugset / Trial / NCT00112645
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
Open-labelTreatment
Summary
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving busulfan and melphalan with or without antithymocyte globulin before transplant and cyclosporine with methylprednisolone or methotrexate after transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in treating young patients with relapsed or refractory solid tumors.
Timeline
- Start
- 2005-04
- Primary completion
- 2010-04
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Background | Busulfan | Small molecule | — | Intravenous |
| Background | Cyclosporine | Peptide | — | — |
| Background | Melphalan | Small molecule | — | Intravenous |
| Background | Methotrexate | Small molecule | — | — |
| Background | Methylprednisolone | Other / unclassified | — | — |